TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.
gurufocus.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignanciesgurufocus.comJun 3
businesswire.comCellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignanciesbusinesswire.comJun 3
zacks.comTScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimateszacks.comMay 6
globenewswire.comTScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.comMay 6
globenewswire.comTScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meetingglobenewswire.comApr 27